CytRx Shares Higher

CytRx Shares Higher

CytRx shares rose 10% on Thursday after the company said updated results from a phase 3 trial of aldoxorubicin in patients with relapsed and refractory soft tissue sarcomas continued to demonstrate significantly prolonged progression-free survival compared to standard treatments. Moreover, the data show that aldoxorubicin can be dosed continuously with minimal to no cardiotoxicity. “Taken together, these findings support aldoxorubicin’s potential as a superior anthracycline treatment for patients suffering with […]

Read More ˃